Leadership Overview
Natera has 6 executives leading key functions including strategy, finance, technology, operations, information systems, and medical oncology.
Driven by innovation, Natera is dedicated to making personalized genetic testing and diagnostics a standard of care, supporting longer, healthier lives through earlier, more targeted interventions.
Driven by innovation, Natera is dedicated to making personalized genetic testing and diagnostics a standard of care, supporting longer, healthier lives through earlier, more targeted interventions.
Leadership Roles at Natera
Steven Chapman - Chief Executive Officer
Steven Chapman, the Chief Executive Officer at Natera, directs the company's overarching strategy and market positioning. Chapman guides Natera's mission to integrate cell-free DNA testing into standard medical practice across oncology, women's health, and organ health. Overseeing global expansion, Chapman ensures Natera's diagnostics enable earlier, more precise interventions, directly supporting the goal of longer, healthier lives. This leadership involves fostering innovation and driving the company's commitment to advancing personalized genetic diagnostics. Chapman's strategic vision shapes Natera's impact on patient care worldwide. The Chief Executive Officer's focus remains on enhancing Natera's leadership in the cfDNA testing market. By championing the company's core values, Steven Chapman solidifies Natera's role in protecting health through advanced genetic insights.
Michael Brophy - Chief Financial Officer
Michael Brophy, the Chief Financial Officer at Natera, manages all financial operations and fiscal strategy. Brophy oversees Natera's financial planning, resource allocation, and investor relations, ensuring the company's economic stability and growth. The Chief Financial Officer's responsibilities include optimizing financial performance to support Natera's mission of advancing personalized genetic testing. Brophy drives fiscal discipline across departments, enabling investments in research and development for oncology, women's health, and organ health diagnostics. This role is critical for sustaining Natera's market leadership and facilitating the expansion of cfDNA testing as a standard of care. Michael Brophy's financial acumen underpins Natera's capacity to deliver innovative solutions that promote longer, healthier lives. The Chief Financial Officer ensures robust financial frameworks are in place to support Natera's global operations and strategic objectives.
Constance O'Sagie - Chief Operating Officer
Constance O'Sagie, the Chief Operating Officer at Natera, oversees the company's global operational efficiency and execution. O'Sagie manages the day-to-day business activities, ensuring seamless integration of Natera's diagnostic services across all functional areas. The Chief Operating Officer's role is crucial in scaling Natera's operations to meet the growing demand for advanced cfDNA testing in oncology, women's health, and organ health. O'Sagie drives process improvements and operational excellence to support Natera's mission of making personalized genetic diagnostics a standard of care. This involves optimizing laboratory workflows, supply chain management, and customer support to facilitate earlier, more targeted interventions. Constance O'Sagie's operational leadership ensures Natera can effectively deliver on its promise of enabling longer, healthier lives through innovative testing solutions. The Chief Operating Officer's strategic oversight guarantees the reliable and efficient delivery of Natera's critical health services.
Rishi Kacker - Chief Technology Officer
Rishi Kacker, the Chief Technology Officer at Natera, leads technological innovation and infrastructure development. Kacker directs the engineering and R&D teams responsible for advancing Natera's cell-free DNA (cfDNA) testing platforms. The Chief Technology Officer's focus is on developing cutting-edge diagnostic solutions that enhance precision in oncology, women's health, and organ health. Kacker ensures Natera's technology supports the company's goal of making personalized genetic testing a standard of care, enabling earlier and more targeted interventions. This involves overseeing the development of scalable and robust technological systems that drive Natera's scientific advancements. Rishi Kacker's leadership is pivotal in translating complex genetic data into actionable insights for improved patient outcomes. The Chief Technology Officer champions the integration of novel technologies to maintain Natera's competitive edge in the diagnostics industry.
Ben Nguyen - Chief Information Officer
Ben Nguyen, the Chief Information Officer at Natera, directs the company's information technology strategy and infrastructure. Nguyen is responsible for managing Natera's digital systems, data security, and IT operations to support the company's global diagnostic services. The Chief Information Officer ensures that Natera's technology platforms are robust, secure, and scalable, facilitating the advancement of cell-free DNA (cfDNA) testing. Nguyen's leadership is vital in enabling Natera's mission to integrate personalized genetic testing into standard care for oncology, women's health, and organ health. This involves implementing advanced IT solutions that enhance data integrity and accessibility for clinical decision-making. Ben Nguyen's focus on information systems supports Natera's commitment to earlier, more targeted interventions and ultimately, longer, healthier lives. The Chief Information Officer champions cybersecurity measures and digital transformation initiatives across the organization.
Minetta Liu - Chief Medical Officer, Oncology
Minetta Liu, the Chief Medical Officer, Oncology at Natera, provides critical medical leadership for the company's oncology diagnostics. Liu guides the clinical strategy and development of Natera's cell-free DNA (cfDNA) testing solutions aimed at improving cancer detection and management. The Chief Medical Officer, Oncology's expertise is essential in translating Natera's scientific innovations into clinically actionable tools for oncologists. Liu champions the integration of these advanced diagnostics into standard patient care pathways, supporting earlier and more precise interventions. This role involves collaborating with research teams and healthcare providers to ensure Natera's oncology offerings meet the highest standards of efficacy and patient benefit. Minetta Liu's medical insights are instrumental in advancing Natera's mission to improve outcomes for cancer patients, contributing to longer, healthier lives. The Chief Medical Officer, Oncology drives the clinical validation and adoption of Natera's groundbreaking cancer diagnostics.
Explore Leadership Teams in Business Services
Founded in 1991, Myriad Genetics is an American molecular diagnostic company specializing in discovering and delivering tests across major diseases. Myriad Genetics is located in Utah.
Company Leadership JD
SR
MG
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham,...
Company Leadership DT
PA
Cytek Biosciences is a leading cell analysis solutions company founded in 1992 and headquartered in Fremont, California with global offices across North America, Europe, and Asia. The company specializes in research and development of advanced cell analysis tools through its patented Full Spectrum Profiling technology. Cytek's product portfolio includes scientific instruments such as the Aurora and Northern Lights systems, cell sorters, reagents, and supporting software that enable high-resolution and high-sensitivity cell analysis for research purposes. The company provides comprehensive solutions for scientific research institutions and laboratories, with its Northern Lights CLC system available for clinical use in China and the European Union. Cytek Biosciences operates in the biotechnology and scientific research services sector, offering both business-to-business and business-to-consumer products through its website cytekbio.com and other distribution channels.
Company Leadership
MY
United BioSource LLC is a global biopharmaceutical services organization that specializes in evidence development solutions designed to support the safety, efficacy, and value assessment of medical products under real-world conditions. The company works closely with pharmaceutical and life sciences organizations to help generate meaningful clinical and real-world evidence that informs regulatory, payer, and healthcare decision-making. Its services are centered on integrating scientific expertise with advanced data analytics and technology-driven platforms to address complex challenges in drug development and commercialization.
Company Leadership
DR
SB
MH
Frequently Asked Questions Regarding Natera Top Executives and Leadership Team
Unlock more people and company data
